Section Review: Oncologic, Endocrine & Metabolic: Topoisomerase I inhibitors in gynaecologic cancers

References

• YANG L, LIU LF, LI JJ, ET AL.: The roles of DNA topoisom-erase in SV 40 DNA replication. UCLA Symp. Mol, Cell, Biol. (1986) 47:315–326.
   Google Scholar
• LIU LF, WANG JC: Supercoiling of DNA template duringtranscription. Proc. Natl. Acad. Sci. USA (1987) 84:7024–7027.
   PubMed Web of Science ®Google Scholar
• WANG JC, GIAVER GN: Action at a distance along a DNA.Science (1988) 240:300–304.
   PubMed Web of Science ®Google Scholar
• KIM RA, WANG JC: A subthreshold level of DNA topoi-somerases leads to the excision of yeast rDNA as ex-trachromosomal rings. Cell (1989) 57:975–985.
   PubMed Web of Science ®Google Scholar
• UEMURA T, OHKURA H, ADACHI Y, ET AL.: DNA topoi-somerase II is required for condensation and separa-tion of mitotic chromosomes in S. pombe. Cell (1986) 50:917–925.
   Google Scholar
• HOLM C, STEARNS T, BOTSTEIN D: DNA topoisomeraseII must act at mitosis to prevent nondisjunction and chromosome breakage. Mol. Cell. Biol. (1989) 9:159–168.
   PubMed Web of Science ®Google Scholar
• WANG JC: Interaction between DNA and anEscbericbia coil protein. J. Mot Biol. (1969) 43:263–272.
   PubMed Web of Science ®Google Scholar
• CHAMPOUX JJ, DULBECCO R: An activity from mammal-ian cells that untwists superhelical DNA - a possible swivel for DNA replication. Proc. Natl. Acad. Sci. USA (1972) 19:143–146.
   Google Scholar
• GELLERT M, MIZUCHI K, O'DEA MH, ET AL.: An enzymethat introduces superhelical turns into DNA. Proc. Natl. Acad. Sci. USA (1976) 73:3872–3876.
   PubMed Web of Science ®Google Scholar
• LIU LF, LIU CC, ALBERTS BM: T4 DNA topoisomerase. Anew ATP-dependent enzyme essential for the initiation of T4 bacteriophage DNA replication. Nature (1979) 281:456–461.
   Google Scholar
• LIU LF: DNA topoisomerases-enzymes that catalyze thebreaking and rejoining of DNA. Ann. Rev. Biochem. (1983) 15:19–24.
   Google Scholar
• WANG JC: DNA topoisomerases. Ann. Rev. Biochem. (1985) 54:665–697.
   PubMed Web of Science ®Google Scholar
• Very thorough review of the mechanism of action of DNA topoisom-erase.
   Google Scholar
• SCHNEIDER E, HSIANG YH, LIU L: DNA topoisomerase as anticancer drug targets. Adv. Pharmacol. (1990) 21:149–183.
   PubMedGoogle Scholar
• Excellent review of the effects of inhibitors of topoisomerase.
   Google Scholar
• DARPA P, MACHLIN PS, RAMIE H, ROTHFIELD NF, CLEVE- LAND DW, EARNSHAW WC: cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa car-boxyl-terminal fragment. Proc. Natl. Acad. Sci. USA (1988) 85:2543–2547.
   Google Scholar
• JUAN CC, HWANG J, LIU AA, ET AL.: Human DNA topoi-somerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. Proc. Natl. Acad. Sci. USA (1988) 85:8910–8913.
   Google Scholar
• WANG JC: DNA topoisomerases: why so many? J. Biol.Chem. (1991) 6:6659–6662.
   Google Scholar
• CHAMPOUX J: Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme. Proc. Natl. Acad. Sci. USA (1976) 73:3488–3491.
   PubMed Web of Science ®Google Scholar
• LYNN RM, BJORNSTI MA, CARON PR, WANG JC: Peptidesequencing and site-directed mutagenesis identify tyro-sine-727 as the active site tyrosine of Saccbarotnyces cerevisiae DNA topoisomerase-L Proc. Natl. Acad. Sci. USA (1989) 86:3559–3563.
   PubMed Web of Science ®Google Scholar
• LIU LF, DARPA P: Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance. In:Important Advances in Oncology (1992):79–89.
   PubMedGoogle Scholar
• Review of resistance mechanisms.
   Google Scholar
• HSIANG YH, LIU LF, WALL ME, ET AL.: DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camp- tothecin analogs. Cancer Res. (1989) 49:4385–4389.
   Google Scholar
• CHEN AY, LIU LF: Mechanisms of resistance to topoisom- erase inhibitors. Cancer Treatment Res. (1994) 73:263-281.Review of resistance mechanisms.
   Google Scholar
• FUJII N, YAMASHITA Y, SAITAH Y, NAKANO H: Inductionof mammalian DNA topoisomerase I mediated DNA cleavage and DNA winding by bulgarein. J. Med. Chem. (1993) 268:13160–13165.
   Web of Science ®Google Scholar
• CHARCOSSET J, SOUES S, LAVAL F: Poisons of topoisom-erases I and 11. Bulletin du Cancer. (1993) 80:923–954.
   PubMedGoogle Scholar
• YOSHINARI T, MATSUMOTO M, FITKASAWA K, KOMATANIH: Inhibition of topoisomerase I and mechanism of cell-line selectivity cytotoxichy of a new antitumor indolocarbazole, NB-506. Proc. Am. Assoc. Cancer Res. (1995) 36:A2626.
   Google Scholar
• SEBOLT JS, SCAVONE SV, PINTER CD ET AL.: Pyrazoloac-ridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res. (1987) 47:4299–4304.
   Google Scholar
• CHEN AY, YU C, GATTO B, LIU LF: DNA minor groovebinding ligands: A new class of mammalian DNA topoi-somerase I inhibitors. Proc. Natl. Acad. Sci. USA (1993) 90:8131–8135.
   PubMed Web of Science ®Google Scholar
• SASAKI Y, TANIGAWARA Y, FUJII H, ET AL.: Phase I andpharmacology study of NB-506. Proc. Am. Soc. Clin. Oncol. (1995) 14A373.
   Google Scholar
• JACKSON RC: The problem of the quiescent cancer cell. Adv. Enzyme Regul. (1989) 29:27–46.
   PubMedGoogle Scholar
• JACKSON RC, SEBOLT JS, SHILLIS JL, LEOPOLD WR: The pyrazoloacridines: Approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest. (1990) 8:39–47.
   PubMed Web of Science ®Google Scholar
• LORUSSO P, WOZNIAK AJ, POLIN L, ET AL.: Antitumorefficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res. (1990) 50:4900–4905.
   Google Scholar
• ROWINSKY E, NOE D, GROCHOW L, ET AL.: Phase I andpharmacokinetic (PK) studies of pyrazoloacridine on single 1–3 hr infusion and daily x 5 day schedules. Proc. Am. Soc. Clin. Oncol. (1994) 13:A360.
   Google Scholar
• WALL ME, WANI MC, COOKE, ET AL.: Plant antitumoragents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotbeca acuminata. J. Am. Chem. Soc. (1966) 88:3888–3890.
   Google Scholar
• PERDUE RE, SMITH RL, WALL ME, HARTWELL JL, ABBOTTBJ. Camptotbeca acuminata Decaisne (Nyssaceae). Source of camptothecin, an antileukemic alkaloid, U.S. Department of Agriculture. Agric. Res. Sem. Tech. Bull. (1990) 14151.
   Google Scholar
• WALL ME: Discovery of camptothecin and taxoL In: Chronicles of Drug Discovery. Lednicer D (Ed.). American Chemical Society, Washington D.C. (1993).
   Google Scholar
• MUGGIA F: Twenty years later: Review of clinical trials with camptothecin sodium (NSC-100880). In: Camp-tothecins: New Anticancer Drugs. Pottuesil M, Pined° H (Eds.). CRC Press, Boca Raton, FL (1995):43–50.
   Google Scholar
• MUGGIA FM, CREAVEN PJ, HANSEN HH, ET AL.: Phase I clinical trial of weekly and daily treatment with camp-tothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother. Rep. (1972) 56:515–521.
   Google Scholar
• MOERTEL CG, SCHUTT AJ, REITEMEIER RJ, HAHN RG: Phase II study of camptothecin in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. (1972) 56:95–101.
   PubMedGoogle Scholar
• GOTTLIEB JA, LUCE JK: Treatment of malignant lym-phoma with camptothecin. Cancer Chemother. Rep. (1972) 56:103–105.
   PubMedGoogle Scholar
• GIOVANELLA BC, STEHLIN JS, WALL ME, ET AL.: DNA topoisomerase I-targeted chemotherapy of human co-lon cancer in xenografts. Science (1989) 246:1046-1048. First demonstration of water-insoluble camptothecins' activity in nude mouse xenografts.
   Google Scholar
• GALLO RC, WHANG-PENG J, ADAMSON RH.: Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer. Inst. (1971) 46:789–793.
   PubMed Web of Science ®Google Scholar
• SUFFNESS M, CORDELL GA: Antitumor alkaloids. In: Chemistry and Pharmacology. Brossi A (Ed.). Academic Press, Orlando (1985).
   Google Scholar
• JAXEL C, KOHN KW, WANT MC, ET AL.: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase E Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. (1989) 49:1465–1469.
   Google Scholar
• LI LH, FRASER TJ, OLIN EJ, BHUYAN BK: Action of camp-tothecin on mammalian cells in culture. Cancer Res. (1972) 32:2643–2650.
   PubMed Web of Science ®Google Scholar
• HORWITZ SB, HORWITZ MS: Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. (1973) 33:2834–2836.
   PubMed Web of Science ®Google Scholar
• HSIANG YH, LLHOU MG, LIU LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camp-tothecin. Cancer Res. (1989) 49:5077–5081.
   PubMed Web of Science ®Google Scholar
• HUANG R, TSUDA H, LIANG J, ET AL.: Topoisomerase I Inhibitors, irinotecan hydrochloride and SN-38 induce apoptosis in leukemia cell lines. Proc. Am. Assoc. Cancer Res. (1994) 35:A5.
   Google Scholar
• HERTZBERG RP, CARANFA MJ, HOLDERN KG, ET AL.: Modification of the hydroxy lactone ring of camp-tothecin: inhibition of mammalian topoisomerase land biological activity. J. Med. Chem. (1982) 32:15–19.
   Google Scholar
• BURKE TG, MI Z: Preferential binding of carboxylate form of camptothecin by human serum albumin. An-nals Biochem. (1993) 212:285–287.
   PubMed Web of Science ®Google Scholar
• MI Z, BURKE TG: Marked interspecies variations con-cerning interactions of camptothecin with serum albu-min. Biochem. (1994) 33:12540–12545.
   PubMed Web of Science ®Google Scholar
• MI Z, BURKE TG: Marked interspecies variations con-cerning interactions of camptothecin analogues with serum albumin. Proc. Am. Assoc. CancerRes. (1995) 36:444.
   Google Scholar
• POTMESIL M.: Catnptothecins, From bench research to hospital wards. Cancer Res. (1994) 54:1431–1439.
   PubMed Web of Science ®Google Scholar
• WALL ME, WANI MC: Chemistry and antitumor activities of camptothecins. In: DNA Topoisomerases in Cancer. Potmesil M, Khon KW (Eds.). Oxford University Press, New York, NY (1991):93–102.
   Google Scholar
• Chemistry discussion.
   Google Scholar
• KAWATO Y, FLTRUTA T, AONUMA M, ET AL.: Antitumoractivity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacy'. (1991) 28:192–198.
   Google Scholar
• ROTHENBERG ML, ROWINSKI EK, KUHN JG, ET AL.: Clini-cal trials and phartnacokinetic studies of CPT-11 in the United States. In: Camptothecins: New Anticancer Drugs. Potmesil M, Pinedo H (Eds.). CRC Press, Boca Raton, FL (1995).
   Google Scholar
• UEHLING DE, NANTHAKUMAR SS, CROOM D, ET AL.: Synthesis, topoisomerase I inhibitory activity, and in vivo evaluation of 11-azacamptothecin analogs. J. Med. Chem. (1995) 38:1106–1118.
   Google Scholar
• LUZZIO MJ, BESTERMAN JM, EMERSON DL, ET AL.: Synthe-sis and antitumor activity of novel soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J. Med. Chem. (1995) 30:395–401.
   Google Scholar
• GIOVANELLA BC, HINZ HR, KOZIELSKI AJ, ET AL.: Com-plete growth inhibition of human cancer xenografts in nude mice by treatment with 20(S)-camptothecin. Can-cer Res. (1991) 51:3052–3055.
   Google Scholar
• PANTAZIS P, KOZIELSKI AJ, MENDOZA JT, ET AL.: Camp-tothecht derivatives induce regression of human ovar-ian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vi-tro. Intl. Cancer (1993) 53:863–871.
   Google Scholar
• PANTAZIS P, HINZ HR, MENDOZA JT, ET AL.: Complete Inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in bnmunodeficient mice by camptothecins. Cancer Res. (1992) 52:3980–3987.
   Google Scholar
• PANTAZIS P, EARLY JA, KOZIELSKI AJ, ET AL.: Regression of human breast carcinoma tumors in immunodefi-dent mice treated with 9-nitro-camptothechu Differen-tial response of nonturnorigenic human breast cells in vitro. Cancer Res. (1993) 53:577–1582.
   Google Scholar
• PANTAZIS P, KOZIELSKI A, RODRIGUEZ R, ET AL.. Thera-peutic efficacy of camptothecin-derivatives against hu-man malignant melanoma xenografts. Melanoma Res. (1994) 4:7–10.
   Google Scholar
• SMITH PL, LIEHR JG, AHMED AE, ET AL.: Pharmacokinet-ics of tritium labeled camptothecin in nude mice. Proc. Am. Assoc. Cancer Res. (1992) 33:32.
   Google Scholar
• GUAFtINO AM, ANDERSON JB, STARKWEATHER DK, ETAL.: Pharmacologic studies of camptothecin (NSC-100880): Distribution, plasma proteinbinding, and billary excre-tion. Cancer Chemother. Rep. (1973) 57:5–14.
   Google Scholar
• GUARINO AM, HART LG, CALL JB, ET AL.: Studies of the physiologic disposition of the antitumor agent, camp-tothecin sodium (NSC-100880) in rodents. Proc. Am. Assoc. Cancer Res. (1969) 10:33.95.
   Google Scholar
• STEHLIN JS, NATELSON EA, HINZ HR, ET AL.: Phase I clinical trial and pharmacokinetics results with oral administration of 20(S)-camptothecin. Im Camp-totbecins: New Anticancer Agents. Potmesil M, Pinedo H (Eds.). CRC Press, Boca Raton, FL (1995):59–65.
   Google Scholar
• GO'rTLIEB JA, GUARINO AM, CALL JB, ETAL.: Preliminary pharmacologic and clinical evaluation of camptothecin (NSC-100880). Cancer Chemother. Rep. (1972) 56:515–521.
   PubMedGoogle Scholar
• GROCHOW LB, ROWINSICY EK, JOHNSON R, ET AL.: Phar-macokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos. (1992) 20:706–712.
   Google Scholar
• ROWINSKY EK, GROCHOW LB, HENDRICKS CB, ET AL.:Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J. Clin. Oncol. (1992) 10:647–656.
   Google Scholar
• KUHN J, BURRIS S, WALL J, ET AL.: Pharmacokinetics ofthe topoisomerase I inhibitor, SK&F 104864. Proc Am. Soc. Clin. Oncol. (1990) 9:70–44.
   Google Scholar
• SASAKI Y, MORITA M, MIYA T, ET AL.: Pharmacokineticand pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Proc Am. Soc. Clin. Oncol. (1992) 11:11.
   Google Scholar
• CHABOT G, DE FORNI M, ABIGERGES D, ET AL.: Clinicaltrials and pharmacology studies of CPT-11 and its active metabolite SN-38 in France: preliminary pharmacoki-netic-pharmacodynamic relationships. In: Camp-tothecins: New Anticancer Agents. Potmesil M, Pinedo H (Eds.). CRC Press, Boca Raton, FL (1995):83–92.
   Google Scholar
• CHABOT G, GOUYETTE A, BISSERY M: Tumor influenceon pharmacokinetics of the camptothecin analogue irinotecan and active metabolite SN-38 in mice. Proc. Am. Assoc. Cancer Res. (1994) 35:A2576.
   Google Scholar
• LOKIEC F, CANCAL P, GAY C, ET AL.: Pharmacokineticsof irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother. Pharmacol. (1995) 36:79–82.
   Google Scholar
• KANEDA N, YOKOKURA T: Nonlinear pharmacokineticsof CPT-11 in rats. Cancer Res. (1990) 50:1721–1725.
   PubMed Web of Science ®Google Scholar
• PANTAZIS P, HARRIS N, MENDOZA J, ET AL.: Conversionof 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro. Eur. J. Haematol. (1994) 53:246–248.
   Google Scholar
• HINZ HR, HARRIS NJ, NATELSON EA, ET AL.: Pharmacok-inetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer Res. (1994) 52:3096–3100.
   Google Scholar
• PANTAZIS P, HARRIS N, MENDOZA J, ET AL.: The role of pH and serum albumin in the metabolic conversion of 9-nitrocamptothecin by human hematopoietic and other cells. Eur. J. Haematol. (1995) 55:211–213.
   Google Scholar
• RUBIN E, WOOD V, BHARTI A, ET AL.: A Phase I andpharmacokinetk study of a new camptothecin deriva-tive, 9-aminocamptothecin. Clin. Cancer Res. (1995) 12:269–276.
   Google Scholar
• CHEN AY, YU C, POTMESIL M, ET AL.: Camptothecinovercomes MDR1-mediated resistance in human KB carcinomas cells. Cancer Res. (1991) 51:6039–6044.
   Google Scholar
• TSURUO T, MATSUZAIU T, MATSUSHITA M, ET AL.: Anti-tumor effect of CPT-11, a new derivative of camp-tothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother, Pbarmacol. (1988) 21:1–74.
   Google Scholar
• POTMESIL M, GIOVANELLA BC, LIU LF, ET AL.: Preclinical studies of DNA topoisomerase I-targeted 9-amino and 10,11-methylenedioxy camptothecins. Im DNA Topoi-somerases in Cancer. Potmesil M, Kohn KW (Eds.). Oxford University Press, New York, NY (1991):299.
   Google Scholar
• POTMESIL M, GIOVANELLA BC, WALL ME, ETAL.: Preclini-cal and clinical development of DNA topoisomerase I inhibitors in the United States. In: Molecular Biology of DNA Topoisomerases and its Application to Chemotherapy. Andoh T, Ikeda H, Oguro M (Eds.). CRC Press, Nagoyajapan (1993):301–311.
   Google Scholar
• SORENSEN M, SEHESTED M, JENSEN P: Characterizationof a human small cell lung cancer cell line resistant to topotecan, a topoisomerase I directed antitumor drug: decreased topoisomerase I and increased topoisom-erase ll level_ Proc. Am. Assoc. Cancer Res. (1994) 35:2724.
   Google Scholar
• DOWNES CS, JOHNSON RT: DNA topoisomerases and DNA repair. Bioassays (1988) 8:179–184.
   PubMed Web of Science ®Google Scholar
• BURRIS HA III, HANAUS10E AR, JOHNSON RK: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J. Natl. Cancer Inst. (1992) 84:816–1820.
   Google Scholar
• KINGSBURY WD, BOEHM JC, JAKES DR, ET AL.: Synthesisof water soluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J. Med. Chem. (1991) 34:98–107.
   Google Scholar
• JOHNSON RK, MCCABE FL, FAUCEIth LF, ET AL.: SK&F104864, a water-soluble analog of camptothecin with broad spectrum activity in preclinical tumor models. Proc. Am. Assoc. Cancer Res. (1989) 30:623.
   Google Scholar
• JOHNSON RK, HERZBERG RP, KINGSBURY WD, ET AL.:Preclinical profile of SK&F 104864, a water-soluble analog of camptothecin. Proc. 6th NCI-EORTC, New Drugs Cancer Ther. Amsterdam (1991)A#301.
   Google Scholar
• POMMIER Y: DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother. Pharrnacol. (1993) 32:103–108.
   PubMed Web of Science ®Google Scholar
• JOHNSON RK, HERTZBERG RP, KINGSBURY WD, ET AL.:Preclinical profile of SK&F 104864, a water soluble analog of camptothecin. Proc. 6th NCI-EORTC, New Drugs Cancer Ther. Amsterdam (1991).
   Google Scholar
• JOHNSON RK, MCCABE FL, GALLIAGHER G, ET AL.: Com-parative efficacy of topotecan, irinotecan, camp-tothecin and 9-arolno-camptothecin in preclinical tumor models. Proc. 7th NU-EORTC, New Drugs Cancer Ther. Amsterdam (1992):85.
   Google Scholar
• CHENG MF, CHATTERJEE S, BERGER NA: Schedule-de-pendent cytotoxicity of topotecan alone and in combi-nation chemotherapy regimens. Oncol. Res. (1994) 6:269–279.
   PubMed Web of Science ®Google Scholar
• PRATESI G, TORTEROTO M, CORTI C, ET AL.: Successful local regional therapy with topotecan of intraperi-toneally growing human ovarian carcinoma xenografts. Br. J. Cancer (1995) 71:525–528.
   Google Scholar
• BLANEY 5, COLE D, BAITS F, GODWIN K, POPLACK D: Intrathecal (IT) administration of topotecan in non human primates. Proc. Am. Assoc. Cancer Res. (1993) 34:A2328.
   Google Scholar
• SLICHENMYER WJ, ROWINSKY EK, DONEHOWER RC, ET AL.: The current status of camptothecin analogues asantitumor agents. J. Natl. Cancer Inst. (1993) 85:271-291. Excellent review of the first clinical trials of camptothecin analogues.
   Google Scholar
• ROWINSKY EK, GROCHOW LB, HENDRICKS CB, ET AL.: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J. Clin. Oncol. (1992) 10:647–656.
   Google Scholar
• CREEMERS Gj, BEIJNEN JH, PLANTING AS, ET AL.: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regi-men. J. Clin. Oncol. (1994) 12:553–559.
   Google Scholar
• WALL JG, BURRIS HA, VONHOFF DD, ET AL.: A Phase I clinical and pharmacokinetic study of the topoisom-erase I inhibitor topotecan given as an intravenous bolus every 21 days. Anticancer Drugs (1992) 3:337–345.
   Google Scholar
• VERWEIJ J, LUND B, BEIJNEN J,ET AL.: Phase land phar-macokinetics study of topotecan, a new topoisomerase I inhibitor. Ann. Oncol. (1993) 4:673–678.
   Google Scholar
• BURRIS HA, AWADA A, KUHN JG, ET AL.: Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs (1994) 5:394–402.
   Google Scholar
• HAAS NB, LACRETA FP, WALCZAK J, ET AL.: Phase I pharmacokinetic study of topotecan by 24-hour con-tinuous infusion weekly. CancerRes. (1994) 54:1220–1226.
   Google Scholar
• SALTZ L, SIROTT M, YOUNG C, ET AL.: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tu-mors, with attempt at dose intensification using recom-binant granulocyte colony-stimulating factor. J. Natl. Cancer Inst. (1993) 85:1499–1507.
   Google Scholar
• ROWINSKY EK, SARTORIUS S, GROCHOW L.: Phase land pharmacologic study of topotecan, an inhibitor of topoisomerase I, with granulocyte colony stimulating factor (G-CSF): Toxicologic differences between con-current and post-treatment G-CSF administration. Proc. Am. Soc. Clin. Oncol. (1992) 11:116.
   Google Scholar
• CREEMERS GJ, SCHELLENS JH, BEIJNEN jI-1, ET AL.: Bioavailability of oral topotecan : a new topoisomerase I inhibitor. Proc. Am. Soc. Clin. Oncol. (1994) 13:324.
   Google Scholar
• KUHN J, RIZZO J, ECKARDT J, ET AL.: Phase I bioavailabil-ity study of oral topotecan. Proc. Am. Soc. Clin. Oncol. (1995) 14:A1538.
   Google Scholar
• PLAXE S, CHRISTEN R, O'QUIGLEY J, ET AL.: Phase I trial of ip topotecan. Proc. Am. Soc. Clin. Oncol. (1993) 12:A360.
   Google Scholar
• ROWINSKY E, GROCHOW L, KAUFMANN S, ET AL.: Se-quence-dependent effects of topotecan (T) and cisplatin (C) in Phase I and pharmacokinetic (PK) study. Proc. Am. Soc. Clin. Oncol. (1994) 13:A361.
   Google Scholar
• MURREN J, FEDELE J, ANDERSON S, ET AL.: Phase I trial of cyclophosphamide and topotecan in refractory can-cer. Proc. Am. Soc. Clin. Oncol. (1995) 14:A1542.
   Google Scholar
• LILENBAUM R, ROSNER G, RATAIN M, ET AL.: Phase I study of taxol and topotecan in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (1994) 13:A319.
   Google Scholar
• ECKARDT J, BURRIS H, RODRIGUEZ G, ET AL.: A Phase I study of the topoisomerase land U inhibitors topotecan and etoposide. Proc. Am. Soc. Clin. Oncol. (1993) 12:A349.
   Google Scholar
• TOLCHER A, O'SHAUGHNESSY J, WEISS R, ET AL.: A Phase I study of topotecan in combination with doxorubicin. Proc. Am. Soc. Clin. Oncol. (1994) 13:A422.
   Google Scholar
• KUDELKA AP, EDWARDS CL, FREEDMAN R, ET AL.: An open Phase U study to evaluate the efficacy and toxicity of topotecan administered iv as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma. Proc. Am, Soc. Clin. Oncol. (1993) 12:A821.
   Google Scholar
• ARMSTRONG D, ROWINSKY E, DONEHOWER R, ROSEN-SHEIN N, WALCZAK J, MCGUIRE W: A Phase II trial of topotecan as salvage therapy in epithelial ovarian can-cer. Proc. Am. Soc. Clin. Oncol. (1995) 14:A769.
   Google Scholar
• MIYASAKA T, SAWADA S, NOKATA K, ET AL.: JP-6017970-A (1985).
   Google Scholar
• KANZAWA F, SUGIMUTO Y, MINATO K, ET AL.: Estab-lishment of a camptothecin analogue (CPT-11)-resis-tant cell line of human small cell lung cancer: characterization and mechanism of resistance. Cancer Res. (1990) 50:5919–5924.
   Google Scholar
• KWATO Y, AONUMA M, HIROTA T, ET AL.: Intracellular roles of SN-38, a metabolite of the camptothecin deriva-tive, CPT-11, in the antitumor effect of CPT-11. Cancer Res. (1991) 51:4187–4191.
   Google Scholar
• NITTA K, YOKOKURA T, SAWADA S, ET AL.: Antitumor activity of a new derivative of camptothecin. In: Recent Advances in Chemotherapy. Tokyo Press, Tokyo, Japan (1985):28–30.
   Google Scholar
• KUNIMITO T, NITTA K, TANAKA T, ET AL.: Antitumor activity of 7-ethyl-10(4-(1-piperidino)-1-piperidino) carbonyloxy-camptothecin, a novel water-soluble de-rivative of camptothecin, against murine tumors. Can-cer Res. (1987) 47:5944–5947.
   Google Scholar
• FRUTA T, YOKOKURA T, MUTAI M: Antitumor activity of CPT-11 against rat Walker 256 carcinoma. Jpn.J. Cancer Chemother. (1988) 15:2757–2760.
   PubMedGoogle Scholar
• BISSERY MC, MATHIEU-BOUE A, LAVELLE F: Preclinical evaluation of CPT-11, a camptothecin derivative. Proc. Am. Assoc. Cancer Res. (1991) 32:402.
   Google Scholar
• BISSERY MC, MATHIEU-BOUE A, LAVELLE F: Experimen-tal antitumor activity of CPT-11. Proc. 7th NCI-EORTC, New Drugs Cancer Ther. Amsterdam (1992)82.
   Google Scholar
• KANEDA N, NAGATA H, FRUTA T, ET AL.: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse Cancer Res. (1990) 50:1715–1720.
   Google Scholar
• ABIGERGES D, CHABOT GG, ARMAND JP, ET AL.: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer pa-tients. J. Clin. Oncol. (1995) 13:210–221.
   Google Scholar
• CLAVEL M, MATH1EU-BOUE A, DUMOR HER A, ET AL.: Phase I study of CPT-11 administered as a daily infusion for 3 consecutive days. Proc. Am. Assoc. Cancer Res. (1992) 33:262.
   Google Scholar
• OHE Y, SASAICI Y, SHINKAI T, ET AL.: Pharmacokinetic with a 5-day continuous infusion of a camptothecin derivative, CPT-11. Proc. Am. Soc. Clin. Oncol. (1991) 10:117.
   Google Scholar
• NEGORO S, FUKUOKA M, MASUDA N, ETAL.: Phase I study of weekly intravenous infusions of CPT-11, a new de-rivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (1991) 83:1164–1168.
   Google Scholar
• TSUI T, KANEDA N, ICADO K, ET AL.: CPT-11 converting enzyme from rat serum: Purification and some proper-ties. J. Pharmacobiodyn. (1991) 14:341–349.
   Google Scholar
• GUPTA E, LESTINGI TM, MICK R, ET AL.: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. (1994) 54:3723–3725.
   Google Scholar
• BAUMER P, DANQUECHIN DE, BERTRAND J, ETAL.: Effects of acetorphan, an enkephalinase inhibitor, on experi- mental and acute diarrhoea. Gut (1992) 33:753–758.
   Google Scholar
• GONCALVES E, DACOSTA L, ABIGERGES D, ETAL.: A new enkephalinase inhibitor as an alternative to lop-eramide in the prevention of diarrhea induced by CPT-11. J. Clin. Oncol. (1995) 13:2144–2146.
   Google Scholar
• HAGIPANTELLI R, SALIBA F, MISSET JL, ETAL.: Pathophysi-ology and therapy of irinotecan induced delayed onset diarrhea: a prospective assessment. Proc. Am. Soc. Clin. Oncol. (1995) 14:A1499.
   Google Scholar
• CLAVEL M, EXTRA JM, ABIGERGES D, ETAL.: FrenchPhase I studies of CPT-11 using 3 different schedules of ad-ministration. Annals Oncol. (1992) 3:50.
   Google Scholar
• MATSUO K, KOHNO K, TAKANO H, SATO S, KIUE A, KUWANO M: Reduction of drug accumulation and DNA topoisomerase ll activity in acquired teniposide-resis-tant human cancer KB cell lines. Cancer Res. (1990) 50:5819–5823.
   PubMed Web of Science ®Google Scholar
• MASUDA N, FUKUOKA M, KUDOH S, ETAL.: Phase land pharmacology study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J. Clin. Oncol. (1994) 12:1833–1841.
   Google Scholar
• MASUDA N, FUKUOKA M, KUDOH S, ETAL.: Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J. Clin. Oncol. (1994) 12:90–96.
   Google Scholar
• OKAMOTO H, NAGATOMO A, KUNITOH H, WATANABE K: A combination Phase I-11 study of carboplatin/iri-notecan plus G-CSF with the Calvert equation in pa-tients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1995) 14:A1150.
   Google Scholar
• SALTZ L, KANOWITZ J, KEMENY N, ETAL.: Phase! trial of irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumors. Proc. Am. Soc. aim Oncol. (1995) 14:A1546.
   Google Scholar
• SUGIYAMA T, TAKEUCHI S, NODA K, YAKUSHIJI M, AND THE CPT-11 STUDY GROUP ON GYNECOLOGIC MALIG-NANCY: Phase I study of irinotecan (CPT-11) in combi-nation with cisplatin on cervical cancer. Proc. Am. Soc. Clin. Oncol. (1994) 13:A856.
   Google Scholar
• TAKEUCHI S, TAKAMIZAWA H, TAICEDA Y, ET AL.: An early Phase II study of CPT-11 in gynecologic cancers. Research group of CPT-11 in gynecologic cancers. jpn. J. Cancer Chemother. (1991) 18:579–584.
   Google Scholar
• TAKEUCHI S, NODA K, YAKUHIJI M, ETAL.: Late Phase II study of CPT-11, a topoisomerase I inhibitor, in ad-vanced cervical carcinoma. Proc. Am. Soc. Clin. Oncol. (1992) 11:A708.
   Google Scholar
• TAKEUCHI S, DOBASHI K, FUJIMOTO S, ETAL.: A late Phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research groups of CPT-11 in gyne-cologic cancers. jpn. J. Cancer Chemother. (1991) 18:1681–1689.
   Google Scholar
• MORI H, ITOH N, KONDOH H, ET AL.: Treatment of recurrent gynaecologic malignancies with a new camp-tothecin derivative. Eur. J. Cancer (1992) 28:613.
   Google Scholar
• KAVANAGH JJ, KUDELICA AP, EDWARDS CL, ETAL.: CPT-11 (irinotecan): Phase II study in refractory squatnous cell carcinoma of cervix. Proc. Am. Assoc. Cancer Res. (1994) 35:A1397.
   Google Scholar
• CHEVALLIER B, LHOMME C, DIERAS V, ETAL.: Phase II trial of CPT-11 in advanced cervical carcinoma. Proc. Am. Soc. Clin. Oncol. (1995) 14:267.
   Google Scholar
• POTKUL RK, PRICE FV, BAILEY H, ET AL.: Irinotecan (CPT-11) in advanced squamous cell carcinoma of the cervix (Phase II). Proc. Am. Soc. Clin. Oncol. (1995) 14:297.
   Google Scholar
• PANTAZIS P, EARLY JA, MENDOZA JT, ETAL.: Cytotoxic efficacy of 9-nitro-camptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res. (1994) 54:771–776.
   Google Scholar
• PANTAZIS P, KOZIELSKI AJ, VARDEMAN DM, ETAL.: Effi-cacy of camptothecin congeners in the treatment of human breast carcinoma. Oncol. Res. (1993) 5:273–281.
   Google Scholar
• PANTAZIS P, KOZIELSKI AJ, RODRIGUEZ R, ETAL.: Thera-peutic efficacy of camptothecin-derivatives against hu-man malignant melanoma xenografts. Melanoma Res. (1994) 4:5–10.
   Google Scholar
• DIXIT R, LOPEZ R, MUELLINER P, ETAL.: A species com-parison of toxicity and pharmacokinetics of 9-amino-20(S)-camptothecin in rodents and dogs. Proc. Am. Assoc. Cancer Res. (1993) 34:A2552.
   Google Scholar
• DAHUR W, BRILLHART N, TAKIMOTO C, ETAL.: A Phase I trial of 9-atuinocamptothecin (9-AC) in adult patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (1994) 13:A345.
   Google Scholar
• TEN BOICKEL HUININK WW, RODENHUIS S, BEIJNEN J, ET AL.: Phase I study of the topoisomerase I inhibitor topotecan. Proc Am. Soc. Clin. Oncol. (1992) 11:110.
   Google Scholar
• RECONDO G, ABBRUZZE J, NEWMAN B, ETAL.: A Phase I trial of topotecan administered by a 24 hour infusion. Proc. Am. Assoc. Cancer Res. (1991) 32:206.
   Google Scholar
• CULINE S, DE FORNI M, EXTRA JM, ETAL. : Phase I study of the camptothecin analogue CPT-11, using a weekly schedule. Proc Am. Soc. Clin. Oncol. (1992) 11:110.
   Google Scholar
• TAGUCHI T, WAKUI A, HASEGAWA K, ET AL.: Phase! clinical study of CPT-11. Jpn. J. Cancer Chemother. (1990) 17:115–120.
   Google Scholar